ArticleJournal of endocrinological investigation2026
The impact of type 2 diabetes on male obesity-associated secondary hypogonadism patients undergoing sleeve gastrectomy.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Testosterone-related indices and adverse glucose-lipid metabolic status in men: a single-center retrospective study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeType 2 diabetes mellitus (T2DM) frequently coexists with male obesity-associated secondary hypogonadism (MOSH). This study aims to determine the impacts of T2DM on both baseline features and postoperative outcomes after metabolic bariatric surgery in MOSH patients.
methodsIn this retrospective, two-arm cohort study, patients with MOSH undergoing laparoscopic sleeve gastrectomy (LSG) between January 2021 and June 2025 were stratified by T2DM status and matched 1:1 by age, yielding 174 patients per group. Weight loss, metabolic parameters and sex hormones were assessed at baseline and 12 months post-LSG.
resultsPreoperatively, the T2DM group exhibited significantly lower levels of total testosterone (TT) (6.19 vs. 7.13 nmol/L, P < 0.001), free testosterone (FT) (0.16 vs. 0.18 nmol/L, P < 0.05) and bioavailable testosterone (BT) (3.88 vs. 4.27 nmol/L, P < 0.01). Postoperatively, two groups achieved similar weight loss and MOSH remission rates. While TT/FT rose markedly and to similar levels in both groups at 12 months post-LSG (TT: 16.67 vs. 17.09 nmol/L, P = 0.251; FT: 0.34 vs. 0.36 nmol/L, P = 0.195), the T2DM group exhibited persistently lower testosterone bioavailability (BT: 8.28 vs. 8.91 nmol/L, P = 0.013).
conclusionT2DM exacerbates the androgen deficiency in MOSH. Although LSG produces substantial and comparable weight loss, glycemic control, and rises in testosterone across groups, patients with T2DM show incomplete recovery of testosterone bioavailability post-LSG, underscoring the need for targeted postoperative monitoring of androgen bioavailability in this population.
Indexed as
Identifiers
42171679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.